Oxford BioDynamics reports good results from EpiSwitch
Oxford Biodynamics
8.10p
16:49 26/04/24
-1.22%
-0.10p
Biotechnology company Oxford BioDynamics announced on Thursday that, using its proprietary technology platform EpiSwitch, it has been successful in diagnosing breast cancer in a Caucasian cohort of patients provided by the Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology (MCMCC) in Poland.
FTSE AIM All-Share
755.28
17:14 26/04/24
n/a
n/a